A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
This Annual Report on Form 10-K (including the following section regarding Management’s Discussion and Analysis of Financial Condition and Results of Operations), or this Annual Report, contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this Annual Report. Additionally, statements concerning future matters, including statements regarding our business, our financial position, the research and development of our products and other statements regarding matters that are not historical are forward-looking statements.
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | % of Total |
|---|---|---|---|---|---|---|
Reportable Segments | — | — | — | $1M | $0M | 100% |
Revenue under collaborative research and development arrangements from affiliated entities | $1M | $0M | $0M | — | — | — |
Revenue under collaborative research and development arrangements | $5M | $1M | — | — | — | — |
Other revenue | $1M | $1M | — | — | — | — |
Other revenue, including from affiliated entities | $0M | — | — | — | — | — |
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 182K | - | - | - | - | - |
| Net Income | -108M | -107M | -135M | -280M | -304M | -166M |
| EPS | $-2.72 | $-3.95 | $-6.09 | $-14.07 | $-17.40 | $-12.84 |
| Free Cash Flow | -89M | -105M | -125M | -217M | -217M | -179M |
| ROIC | -102.1% | -78.4% | -2031.8% | -60.6% | -76.0% | -36.1% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.00 | 0.29 | 0.07 | 0.24 | 0.17 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -90M | -112M | -144M | -268M | -301M | -124M |
| Operating Margin | -49202.9% | - | - | - | - | - |
| ROE | 0.0% | -115.4% | -115.1% | -125.8% | -76.0% | -36.1% |
| Shares Outstanding | 54M | 27M | 22M | 20M | 17M | 13M |
INOVIO PHARMACEUTICALS, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
INOVIO PHARMACEUTICALS, INC. (INO) has a 5-year average return on invested capital (ROIC) of -62.8%. This is below average and may indicate limited pricing power.
INOVIO PHARMACEUTICALS, INC. (INO) has a market capitalization of $59M. It is classified as a small-cap stock.
INOVIO PHARMACEUTICALS, INC. (INO) does not currently pay a regular dividend.
INOVIO PHARMACEUTICALS, INC. (INO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
INOVIO PHARMACEUTICALS, INC. (INO) generated $-105 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
INOVIO PHARMACEUTICALS, INC. (INO) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
INOVIO PHARMACEUTICALS, INC. (INO) reported earnings per share (EPS) of $-3.95 in its most recent fiscal year.
INOVIO PHARMACEUTICALS, INC. (INO) has a return on equity (ROE) of -115.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for INOVIO PHARMACEUTICALS, INC. (INO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
INOVIO PHARMACEUTICALS, INC. (INO) has a book value per share of $2.52, based on its most recent annual SEC filing.